Phaseline

Companies › Prime Medicine

Prime Medicine: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Nov 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PM577a
Prime editing therapy to correct p.H1069Q mutation in ATP7B gene
ATP7BPhase 1Wilson DiseaseNov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07748403PM577aPhase 1Wilson DiseaseMetabolic and endocrineNov 2028

From the company's SEC filings

Cash and short-term investments of $95m on 2026-06-30; operating cash outflow about $170m a year; runway about 7 months at that burn, to Jan 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ATP7B (1)

Companies with the same targets

Vivet Therapeutics SAS Ultragenyx Pharmaceutical Orphalan

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.